Today, the FDA issued an updated warning of biotin interference with certain laboratory tests. The FDA remains concerned about certain laboratory tests that have not addressed the risk of biotin interference. For example, the FDA has continued to receive adverse events reports indicating biotin interference caused falsely low troponin results.
Clinical Lab Products interviewed Veravas CEO, Carroll E. Streetman Jr., about the present and future of biotin interference removal.
True Diagnostics, Inc., a leading company for Point of Care answers, and Veravas, an emerging diagnostic company focusing on proprietary sample preparation products and new diagnostic tests, announced today their Strategic Alliance in the commercialization of VeraTest Biotin.
Veravas, Inc., an emerging diagnostic company, today announced the appointment of Carroll E. Streetman Jr., as chief executive officer. Mr. Streetman brings over 45 years of experience in highly relevant healthcare industry experience to the position.
Medical Laboratory Observer shared news of the launch of the Veravas biotin interference product portfolio, including VeraTest Biotin, VeraPrep Biotin and VeraBind Biotin.
Veravas, Inc. is showcasing for the first time, a newly launched portfolio of laboratory products to detect and manage biotin interference at the American Association for Clinical Chemistry (AACC) annual meeting on August 4-8, 2019 in Anaheim, California.
Veravas has launched their portfolio of products to improve the accuracy of current diagnostic test results by detecting and managing biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin. The new VeraBind Biotin will also support diagnostic manufacturers in redeveloping lab assays to be biotin-interference-free.
Alex Wittenberg at the Minneapolis/St. Paul Business Journal published a profile of Veravas, highlighting both its long-term potential in the billion-dollar IVD market and the upcoming launch of its first suite of products.
Veravas, Inc., has appointed eight members to its Advisory Board. The board is comprised of leaders in diagnostics, healthcare, and business development who will provide counsel and guidance to Veravas.
Veravas, Inc., has appointed Joshua Soldo as the chief scientific officer and Carmen Wiley, Ph.D., as chief clinical officer. Mr. Soldo and Dr. Wiley have made significant contributions towards the development of Veravas technology and as part of the executive team